Sutro Biopharma (STU:S090) Short Percentage of Float


STU:S090 Sutro Biopharma Inc STU:S090
45 GF Score
Price €6.24
GF Value €2.66
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:S090 vs CCCC, OCGN, FULC: Short Percentage of Float Comparison

For the Biotechnology subindustry, Sutro Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Short Percentage of Float falls into.


STU:S090
45GF Score
Sutro Biopharma Inc STU:S090
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sutro Biopharma (STU:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €6.24 is trading 134.4% above its estimated GF Value™ of €2.66.

Key valuation signals for STU:S090:

  • Short Percentage of Float:
  • GF Value™: €2.66 vs. price of €6.24 (134.4% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STU:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USAS090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STU:S090

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.24
Price
€2.66
GF Value